227 Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01). (September 2015) - Pineda Losada, E.; Salud, A.; Vila-Navarro, E.; Safont, M.J.; Garcia-Giron, C.; Aparicio, J.; Vera, R.; Escudero, M.P.; Casado, E.; Bosch, C.; Bohn, U.; Perez Carrion, R.M.; et al.